Should we really worry about "launch delays" of new drugs in OECD countries?

Eur J Health Econ. 2007 Mar;8(1):1-3. doi: 10.1007/s10198-006-0022-5.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Bias
  • Cost Control
  • Developed Countries*
  • Drug Approval / economics
  • Drug Approval / organization & administration*
  • Europe
  • Humans